myasthenia gravis new treatment 2020
"Patients with this devastating disease can experience chronic and potentially life-threatening muscle weakness that has a major impact on their quality of life, and more treatment options are needed. A Good Life with Bad Muscles; Positively MG; Unmasking Myasthenia Gravis; COVID-19 Info. (2014) 18:947–61. The results of the REGAIN trial led to approval for the use of eculizumab in refractory generalized, AChR antibody (AChRAb) positive MG by the FDA, Health Canada, the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in the US, Canada, Europe and Japan respectively. A Phase 3, Randomized Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis | Clinical Research Trial Listing (Generalized Myasthenia Gravis | Myasthenia Gravis generalised) (TX217967). Christadoss P, Tüzün E, Li J, Saini SS, Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Li X, Kimberly RP. Current therapies for myasthenia gravis (MG) are limited, and many investigations have recently focused on target-specific therapies. Daily science news on research developments and the latest scientific innovations, The latest engineering, electronics and technology advances, The most comprehensive sci-tech news coverage on the web. Drachman DB. CD20 is a transmembrane protein expressed by B cells, but not by long-lived plasma cells and plasmablasts. J Neurol. doi: 10.1016/j.nmd.2017.03.007, 95. Curr Opin Neurol. The subsequent autologous hematopoetic transplantation helps in recovery from the post-conditioning aplasia and enhances immunotolerance by increasing regulatory T cells, reducing autoantibodies and rejuvenating thymic function (102, 103). This may due to persisting memory B cells and long lived plasma cells which can be localized in secondary lymphoid organs and can replenish short lived plasma cells that secrete antibodies. doi: 10.3233/JND-170294, 76. ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response. All adverse events were mild to moderate in severity, with no subjects requiring premature discontinuation due to AEs (61). (2017) 8:100. doi: 10.1007/s13317-017-0100-y, 79. COVID-19 Updates doi: 10.1097/00019052-199912000-00014, 115. With these attractive advantages, SCIG was used initially in primary immunodeficiency disorders and was as effective as IVIG in preventing infections with a lower incidence of serious adverse events (113). In a phase I randomized placebo controlled study to evaluate safety, healthy subjects were randomized to single infusion of intravenous or subcutaneous doses of 1, 4, or 7 mg/kg of razonolixizumab. 59. The availability of more focused immune therapies provides greater treatment options for both patients and treating physicians in the management of MG. A favourable benefit-side effect profile and more rapid onset of action are advantages over current ISTs. These treatments usher in a new era of more focused MG management that promises to improve the lives of people with MG. MG is an antibody mediated disease in which the immunopathogenesis is T cell driven and there exists a complex interplay between CD4+ T cells and B cells. (2020) 11:240. doi: 10.3389/fimmu.2020.00240, 77. Conventional treatment may be complicated for some because of a wide range of … doi: 10.2174/157015909790031166, 111. Thus SCIG offers a novel, efficacious and patient-friendly alternative to IVIG in maintenance therapy for MG, although it has not been tested for acute management of MG. Additionally, its corticosteroid-sparing effects have not been established. Your doctor might use several tests, including: Fc receptors and immunoglobulin binding factors. The major adverse effect of this therapy is the cytokine releasing syndrome (CRS) which can range from mild constitutional symptoms to severe CRS leading to multi-organ dysfunction (96). MG treatment also includes self-care: getting plenty of sleep, resting your eyes, pacing your activity, eating healthy foods, exercising, and managing your stress. Gable KL, Guptill JT. Elevated BAFF levels have been identified in patients with MG, highlighting it as a potential treatment target (81). Weiss J-M, Cufi P, Le Panse R, Berrih-Aknin S. The thymus in autoimmune myasthenia gravis: paradigm for a tertiary lymphoid organ. doi: 10.1007/s11926-012-0256-4, 85. (2009) 7:337–42. (2010) 95:185–8. The presentation took place on Saturday, October 3, 2020 at the Myasthenia Gravis Foundation of America (MGFA) 2020 Virtual Scientific Session. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. (2019) 2019:e3290894. The antisense oligonucleotide EN101, or Monarsen, targets exon 2 of the AChE mRNA and results in AChE-R mRNA being more susceptible to destruction which decreases its activity, and hence maintains levels of acetylcholine in the synaptic cleft (115). Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal fcR blockade. The direct effects of RTX include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy. The binding of BAFF to B cell receptor promotes the survival of the autoantibody-producing B cells by preventing their apoptosis. Ann N Y Acad Sci. BioMed Res Int. doi: 10.1002/mus.25597, 71. Ling LE, Hillson JL, Tiessen RG, Bosje T, Iersel MP, Nix DJ, et al. The editor and reviewers' affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review. Rituximab for Myasthenia Gravis; Rozanolixizumab (UCB7665) Subcutaneous Immunoglobulin (SCIg) for Myasthenia Gravis; Tirasemtiv (CK-2017357) Zilucoplan; Columns. 74. Neurology. VB planned the review, supervised DM in his review, wrote and edited the manuscript. The presumed, increased effectiveness of a patient's own T cells against the malignancy is thought to occur by redirecting the native T cells against selected antigens expressed only by the tumor cells. doi: 10.1002/mus.25973, 66. A phase III study is currently underway to evaluate the efficacy and safety of efgartigimod 10 mg/kg per week for 26 weeks in patients with generalised AChRab positive MG (28). Neurology. J Neuroimmunol. Front Immunol. The dosage schedule was induction with 900 mg on days 0, 7, 14, and 21; 1200 mg at week 4; and then maintenance dosing of 1,200 mg every second week for 26 weeks. Front. Tocilizumab has been reported to be beneficial in patients with refractory MG, one of whom failed to benefit with RTX (94). Myasthenia gravis (pronounced My-as-theen-ee-a grav-us) comes from the Greek and Latin words meaning "grave muscular weakness." The evidence for efficacy in MuSK MG is more robust, although randomized controlled trials are lacking. doi: 10.4061/2011/939520, 69. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. 23
Available online at: https://www.hindawi.com/journals/ad/2011/939520/ (accessed March 22, 2020), 84. A recent phase II randomized placebo-controlled trial compared two doses of subcutaneous zilucoplan in patients with moderate to severe generalised MG (defined as QMG score ≥ 12), and positive AChR antibodies. JAMA Neurol. doi: 10.1016/j.neurol.2013.02.005, 12. (2012) 1274:68–76. doi: 10.1172/JCI97911, 55. B-Cell-Activating factor and autoimmune myasthenia gravis. Under the influence of the Tfh subset of CD4 T cells and with regulatory Tfr CD4 T cells being defective, B cells differentiate into memory B cells, plasmablasts and plasma cells in the thymic germinal centers (65). A rapid reduction in all IgG subclass levels was observed in the first week after treatment, and further decreases to a total 70% reduction from baseline levels with subsequent doses. People with MG have every reason to be hopeful - new treatment choices will become a reality in the next few years. Expert Opin Ther Targets. However, factors to consider in assessing these reports are whether these patients had received adequate trials with other immunosuppressants prior to transplant, and whether using only high dose cyclophosphamide induction, without transplant, would have induced sustained remission (106). The global myasthenia gravis treatment market was valued at around USD 1,011.1 million in 2017 and is expected to grow at a CAGR of 12.1% during the forecast period. In rat models of MG, treatment with anti-FcRn-antibody showed significant reduction in severity of symptoms and lowering of total and anti-AChR IgG levels providing pre-clinical proof of concept (52). Biologics. Myasthenia gravis: the role of complement at the neuromuscular junction. Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Additional studies of Monarsen are not underway at this time. Efgartigimod: a novel antibody depletion therapy in myasthenia gravis. The data for the use of HSCT in various refractory immune mediated neurological disorders have been accumulating over the past two decades, most notably for multiple sclerosis (99, 100). Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. Mice transgenic for baff develop lymphocytic disorders along with autoimmune manifestations. Intravenous immunoglobulin for myasthenia gravis. doi: 10.1007/s40262-019-00742-8, 25. Rituximab treatment of myasthenia gravis: a systematic review: rituximab in myasthenia gravis. Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. (2018) Available online at: https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma (accessed April 3, 2020), 98. Guo Y, Tian X, Wang X, Xiao Z. B-Cell-Activating Factor and Autoimmune Myasthenia Gravis. JAMA Neurol. Alabdali M, Barnett C, Katzberg H, Breiner A, Bril V. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. The most common adverse events were headache (38.9%), vomiting (25%), nausea (19.4%), and pyrexia (19.4%), all occurring more frequently with intravenous administration compared to subcutaneous treatment. Neurol., 30 June 2020
These findings suggest a relatively greater benefit of rituximab earlier in the disease course. RVT 1401 is a fully humanized monoclonal FcRn antibody for subcutaneous or intravenous injection. Soliris is currently targeting patients anti-AchR antibody-positive MG. (2012) 6:277–87. The "Myasthenia Gravis - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.. Cell Mol Life Sci. Liu A, Lin H, Liu Y, Cao X, Wang X, Li Z. There were no safety concerns or increased infections (59). Howard JF. Argenx, a Belgian drug maker, recently announced a successful phase 3 ADAPT trial of its experimental drug, efgartigimod. Guidon AC, Juel VC. Although bortezomib may be promising in MG, further studies are needed. (2003) 126:1922–8. The fcRn inhibitor rozanolixizumab reduces human serum igG concentration: a randomized phase 1 study. (2015) 8:316–27. Soliris ® (eculizumab) Injection, for Intravenous Use. Semin Immunol. However, some of these same actions and other factors such as increased blood viscosity, rapid exposure to high foreign protein load and rapid intravenous volume expansion lead to the frequent adverse effects of IVIG ranging from 2.5 to 87.5% with repeated infusions (111). None of these trials have included seronegative MG patients though this group of patients may resemble antibody positive patients in response to immune therapies (62, 63). Front Immunol. Broad-based immunotherapies, such as corticosteroids, azathioprine, mycophenolate, tacrolimus, and cyclosporine, have been effective in controlling symptoms of myasthenia. The study showed clinical benefits across several endpoints, including QMG, MGC and MG-ADL scores as well as marked reduction of total IgG and AChRab levels. Because women of reproductive age constitute a large proportion of early-onset MG cases (58), interventions compatible with pregnancy are much needed. The antibodies secreted by the plasma cells in AChR antibody positive MG are mainly of IgG1 and IgG3 subclass (8, 9). The higher dose group (0.3 mg/kg daily) achieved significantly lower mean QMG and MG ADL scores (primary end points) and also lower MG composite (MGC) and better MGQOL (secondary end points) at 12 weeks compared to baseline and no patient required rescue therapy. There were no serious side effects reported and minor side effects included injection site reactions (46). doi: 10.1007/s00415-008-3002-0, 15. A limiting factor is the potential for development of sensory neuropathy observed in 30–40% of those treated with bortezomib, and this neuropathy is disabling and permanent in some patients (87). These studies of complement inhibitors and FcRn inhibitors are not without certain limitations. A significant reduction in exacerbation rates, MG related hospitalization and rate of rescue therapy was seen in the double blind study and most patients reported global clinical improvement. Muscle Nerve. IVIG is a useful treatment option when a rapid response is required in worsening or poorly controlled MG. J Clin Invest. Articles, Neurology Unit, Gugliemo da Saliceto Hospital, Italy. (2011) 37:136–43. Kaufer D, Soreq H. Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms. Cusick MF, Libbey JE, Fujinami RS. Infections occurred in about 19% of patients including infections with pseudomonas, cytomegalovirus and aspergillus as well as septic shock. Muscular Dystrophy Association. In the open label extension of REGAIN where 117 patients received 1,200 mg every 2 weeks for a median of 22.7 months, there was 1 case of meningococcal meningitis which resolved with antibiotics. FcRn inhibition also has the potential to alter serum levels of therapeutic monoclonal antibodies and the pharmacokinetic interactions among these agents remain unexplored (64). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Subcutaneously administered immunoglobulin (SCIG) has advantages over IVIG since the slow and sustained intravascular absorption avoids the abrupt vascular volume load, and subcutaneous administration eliminates the need for intravascular access. RTX also increases Treg cells which favourably influences MG immunology. J Neuroimmunol. Thank you for taking your time to send in your valued opinion to Science X editors. However, recent pathological evidence based on samples from external intercostal muscle biopsies from patients with SNMG showed complement deposition at the NMJ, suggesting importance of complement in this subgroup of patients with MG (23). While initially recognized as the mediators of passive transfer of immunity from mother to fetus, their role in protecting IgG from lysosomal degradation and prolonging the half-life of immunoglobulins, has been recognized subsequently (50). This is despite that most of the data for RTX in myasthenia comes from single centre experiences and case series and its use remains an off-label treatment for myasthenia. This site uses cookies to assist with navigation, analyse your use of our services, and provide content from third parties. doi: 10.1517/14728222.2014.877891, 11. Researchers are also exploring better ways to treat myasthenia gravis by developing new tools to diagnose people with undetectable antibodies and identify potential biomarkers (signs that can help diagnose or measure the progression of a disease) to predict an individual’s response to … A phase I placebo controlled study in 50 subjects examined both single (at 0.3, 3, 10, 30, and 60 mg/kg) and multiple ascending doses (four weekly doses of 15 or 30 mg/kg). (2006) 2:271–9. Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG). doi: 10.1034/j.1600-0404.2003.00209.x, 64. doi: 10.1126/scitranslmed.aan1208, 60.
Birmanns B, Brenner T, Abramsky O, Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. The development and function of regulatory t cells. The immunological process in MG begins when immune tolerance is broken by a hitherto unidentified trigger, probably infectious agents, with “molecular mimicry” between the infectious antigen and the acetylcholine receptor(AChR) protein (4). Most of the second generation anti-CD20 agents such as ocrelizumab, ofatumumab, obinutuzumab, veltuzumab, and ofatumumab have the advantage of being fully-humanized and thus may be better tolerated and more efficacious in haematological malignancies and autoimmune disorders (78, 79). 32. There are various steps at which B cells can be targeted either directly or indirectly. This modification confers a longer half life of the antibody due to recycling through the FcRn pathway. Also, since long lived plasma cells lacking CD20 are not targeted by RTX, any clinical benefits may be transient and would require chronic infusions—beyond the 2 cycles in the study— to maintain the effects (76). FDA. doi: 10.1212/WNL.0000000000007605, 65. This research could reveal new therapies for neuromuscular diseases like myasthenia gravis. The company plans to seek U.S. approval of the drug by the end of year as a potential new treatment for patients with generalized myasthenia gravis (gMG), a … doi: 10.1212/WNL.0000000000004341. These agents include terminal complement C5 inhibitors, Fc receptor inhibitors, B cell depleting agents (anti CD 19 and 20 and B cell activating factor [BAFF)]inhibitors), proteosome inhibitors, T cells and cytokine based therapies (chimeric antigen receptor T [CART-T] cell therapy), autologous stem cell transplantation, and subcutaneous immunoglobulin (SCIG). The most promising anti CD19 agents are blinatumomab, SAR3419 and MEDI-551 which are currently in phase II studies in haematological malignancies (79). Autoreactive T cells that escape this process or arise de novo, are kept in check in the peripheral circulation by a subset of CD4+ cells called Treg cells that bring about apoptosis, anergy or suppression of autoreactive cells (3). [Epub ahead of print]. The antigen presenting cells submit the AChR to the CD4+ cells leading to upregulation of proinflammatory cytokines such as interleukins and tumor necrosis factors (5). No use, distribution or reproduction is permitted which does not comply with these terms. Stanford investigators regularly participate in research studies to better understand diseases like myasthenia gravis and to investigate new treatment approaches. doi: 10.1212/WNL.0000000000004365, 39.